Browsing Tag
zanidatamab
3 posts
Ziihera FDA approval unlocks $250m for Zymeworks as Jazz expands HER2 drug into first-line gastric cancer
The FDA has approved two Ziihera-based first-line regimens for HER2-positive advanced gastroesophageal adenocarcinoma, triggering a $250 million payment to Zymeworks and giving Jazz a much larger commercial opportunity.
Zymeworks (ZYME) to buy Theravance (TBPH) for $929m in cash plus ampreloxetine CVR
Zymeworks (ZYME) to acquire Theravance (TBPH) for $17/share plus CVR, $929M equity value. Non-recourse OMERS financing minimises ZYME's cash at risk.
Jazz Pharmaceuticals’ zanidatamab shows promising results in HER2-positive biliary tract cancer
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) has released pivotal new data from its Phase 2b HERIZON-BTC-01 clinical trial assessing…